CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that it has entered into definitive securities purchase agreements with certain institutional and accredited investors for up to $100 million in gross proceeds through a private placement.

CAMP4 intends to use the net proceeds from the private placement to fund the preclinical and clinical development of its SYNGAP1 program, working capital, and general corporate purposes.

“With this financing we are well positioned to bring a potential first-in-class treatment for SYNGAP1-related disorders into the clinic,” said Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4. “This investment marks a critical milestone as we continue our mission of developing potentially disease modifying medicines for patients with disorders marked by suboptimal gene expression.”

The private placement is comprised of an initial upfront financing of $50 million in gross proceeds in exchange for 26,681,053 shares of common stock priced at $1.53 per share of common stock sold at the initial closing, 36,361 shares of common stock priced at $1.65 to certain directors, employees and consultants of CAMP4 at the initial closing, and 6,003,758 pre-funded warrants in lieu of common stock for $1.5299 for each pre-funded warrant sold in lieu of common stock at the initial closing. In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for up to 32,721,172 shares of common stock (or, for certain investors, pre-funded warrants in lieu of common stock), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

Concurrently with the financing, James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D., have resigned from the Board of Directors. In conjunction, the CAMP4 Board of Directors has appointed Doug Williams, Ph.D., as Board Chair, while Steven Holtzman has transitioned from Board Chair to Independent Director. Additionally, the Company has elevated Daniel Tardiff, Ph.D., the Company’s SVP, Head of Discovery, to its Chief Scientific Officer, effective October 1, 2025. David Bumcrot, Ph.D., will transition to the role of Scientific Fellow. Both will work closely with board member Murray Stewart, DM FRCP, who will become Chair of the Company’s Research and Development committee.

The financing is being led by new investor Coastlands Capital, and includes participation from additional new and existing investors including Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners and the SynGAP Research Fund.

Leerink Partners is acting as lead placement agent for the financing. Piper Sandler & Co., Cantor Fitzgerald, and Wedbush & Co. are acting as co-placement agents for the financing.

Board and Management Changes:

• Dr. Williams joined the CAMP4 Board of Directors in March 2025 and brings extensive life science leadership to CAMP4, having contributed to the development of several transformative drugs. He was previously President of R&D at Sana Biotechnology and the Founding President & CEO of Codiak BioSciences. Prior to Sana, Dr. Williams served as EVP of R&D at Biogen, and earlier in his career was CEO of ZymoGenetics (acquired by BMS), and held leadership roles at Seattle Genetics, Amgen, and Immunex. Over the course of his career, he has served on the Board of Directors and Advisory Boards of more than two dozen biotechnology companies.
• Dr. Tardiff joined CAMP4 in 2023 and has been instrumental in leading the Company’s drug discovery efforts to advance a pipeline of needed therapies toward the clinic. He was previously a team leader in the Rare Disease Research Unit at Pfizer, exploring genetic medicines for rare neurological disorders. Prior to Pfizer, Dr. Tardiff was a scientific co-founder of Yumanity, where he led a team discovering novel therapeutics for the treatment of neurodegenerative diseases, including a clinical-stage small molecule in development for Parkinson’s disease.

The securities offered in this private placement, including the shares underlying the pre-funded warrants, are being sold in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “SecuritiesAct”), or under any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The investors have been granted customary resale registration rights for the shares of common stock issuable upon exercise of the pre-funded warrants issued to them in the financing.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the securities described herein, nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

For further information, please see the Company’s current report on Form 8-K to be filed with the SEC.